Clinical implications of pharmacogenomics for tardive dyskinesia

Pharmacogenomics Journal

Volumn 4, Issue 2, 2004, Pages 77-87

  Muller D J ^a   Shinkai, T ^a   De Luca, V ^a   Kennedy, James L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN E; CATECHOL METHYLTRANSFERASE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; DOPAMINE TRANSPORTER; DRUG METABOLIZING ENZYME; ESTROGEN RECEPTOR ALPHA; LITHIUM; MANGANESE SUPEROXIDE DISMUTASE; NEUROLEPTIC AGENT; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; OPIATE RECEPTOR; SEROTONIN 2A RECEPTOR;

AGING; ARTICLE; CIGARETTE SMOKING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; ETHNOLOGY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HOMOZYGOSITY; HUMAN; INVOLUNTARY MOVEMENT; LONG QT SYNDROME; MEDICAL LITERATURE; MEDLINE; NEUROPSYCHOLOGICAL TEST; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; SAMPLE SIZE; SCHIZOPHRENIA; SCORING SYSTEM; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

ANIMALS; CLINICAL TRIALS; DYSKINESIA, DRUG-INDUCED; HUMANS; PHARMACOGENETICS;

EID: 16544368420     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500233     Document Type: Article

References (85)

1. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry 2000; 34: 355-369.
2. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 18: 701-715.
3. Held T, Weber T, Krausz H, Ahle G, Hager B, Alfter D et al. Clinical characteristics of patients with tardive dyskinesias. Fortschr Neurol Psychiatry 2000; 68: 321-331.
4. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry 2000; 61: 27-32.
5. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical anti-psychotics in very high risk patients. Biol Psychiatry 2003; 53: 1142-1145.
6. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-119.
7. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487.
8. Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977; 12: 431-450.
9. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61: 15-20.
10. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl) 1990; 102: 474-478.
11. Rosengarten H, Schweitzer JW, Friedhoff AJ. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 1994; 49: 663-667.
12. O'Callaghan E, Larkin C, Kinsella A, Waddington JL. Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia. Br J Psychiatry 1990; 157: 578-584.
13. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981; 138: 1618-1619.
14. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375-379.
15. de Carvalho Aguiar PM, Ozelius LJ. Classification and genetics of dystonia. Lancet Neurol 2002; 1: 316-325.
16. Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003; 53: S16-S23, discussion S23-S15.
17. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 175-187.
18. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-1671.
19. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998; 32: 101-106.
20. Ellingrod VL, Schultz SK, Arndt S. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy 2002; 22: 1416-1419.
21. Lam LC, Garcia-Barcelo MM, Ungvari GS, Tang WK, Lam VK, Kwong SL et al. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 2001; 34: 238-241.
22. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997; 131: 174-179.
23. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23-26.
24. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998; 32: 107-113.
25. Jaanson P, Marandi T, Kiivet RA, Vasar V, Vaan S, Svensson JO et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 2002; 162: 67-73.
26. Nikoloff D, Shim JC, Fairchild M, Patten N, Fijal BA, Koch WH et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J 2002; 2: 400-407.
27. Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995; 15: 211-216.
28. Ohmori O, Kojima H, Shinkai T, Terao T, Suzuki T, Abe K. Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients. Psychiatry Res 1999; 87: 239-244.
29. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-452.
30. Lohmann PL, Bagli M, Krauss H, Muller DJ, Schulze TG, Fangerau H et al, CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry 2003; 36: 73-78.
31. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 1999; 125: 803-808.
32. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
33. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5: 410-417.
34. Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105: 498-501.
35. Chong SA, Tan EC, Tan CH, Mythily. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003; 28: 185-189.
36. Matsumoto C, Ohmori O, Shinkai T, Hori H, Nakamura J. Genetic association of functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) with tardive dyskinesia in Japanese patients with schizophrenia. (submitted).
37. Segman RH, Heresco-Levy U, Yakir A, Goltser T, Strous R, Greenberg DA et al. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry 2002; 51: 261-263.
38. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of Taql A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997; 41: 827-829.
39. Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105: 774-778.
40. Inada T, Dobahi I, Sugita T, Inagaki A, Kitao Y, Matsuda G et al. Search of a susceptiblity locus to tardive dyskinesia. Hum Psychopharmacol 1997; 12: 35-39.
41. Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002; 7: 695-705.
42. Chong SA, Tan EC, Tan CH, Mythily, Chan YH. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet 2003; 116B: 51-54.
43. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2: 139-145.
44. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the Mscl polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21: 17-27.
45. Lovlie R, Daly AK, Blennerhassett R, Ferrier N, Steen VM. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. Int J Neuropsychopharmacol 2000; 3: 61-65.
46. Rietschel M, Krauss H, Muller DJ, Schulze TG, Knapp M, Marwinski K et al. Dopamine D3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 2000; 250: 31-35.
47. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4: 247-253.
48. Macciardi F, Verga M, Pedrini S, Cavallaro R, Bongiorno F, Zanchi P et al. Dopamine receptor genes and tardive dyskinesia. Am J Hum Genet 1997; 74: 626.
49. Scharfetter J, Albus M, Hornik K, Fuchs R, Melamed G, Lesch F et al. Association of tardive dyskinesia and dopamine D3 and D4 receptor gene polymorphism. Mol Psychiatry 1999; 4: S85.
50. Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001; 44: 95-98.
51. Garcia-Barcelo MM, Lam LC, Ungvari GS, Lam VK, Tang WK. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2001; 108: 671-677.
52. Gaitonde EJ, Morris A, Sivagnanasundaram S, McKenna PJ, Hunt DM, Mollon JD. Assessment of association of D3 dopamine receptor Mscl polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders. Am J Med Genet 1996; 67: 455-458.
53. Woo SI, Kim JW, Rha E, Han SH, Hahn KH, Park CS et al. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin Neurosci 2002; 56: 469-474.
54. Segman RH, Lerer B. Genetics of drug-induced tardive dyskinesia. In: Lerer B (ed) Pharmacogenetics of Psychotropic Drugs. Cambridge University Press: Cambridge, UK 2002; pp 245-266.
55. Daly G, Hawi Z, Fitzgerald M, Gill M. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry 1999; 4: 192-196.
56. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001; 6: 225-229.
57. Tan EC, Chong SA, Mahendran R, Dong F, Tan CH. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001; 50: 144-147.
58. Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001; 6: 230-234.
59. Herken H, Erdal ME, Bake O, Savas HA. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene. Eur Psychiatry 2003; 18: 77-81.
60. Segman RH, Lerer B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol Psychiatry 2002; 7: 137-139.
61. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000; 152: 408-413.
62. Zhang ZJ, Zhang XB, Sha WW, Reynolds GP. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002; 7: 670-671.
63. Chong SA, Tan EC, Tan CH, Mahendren R, Tay AH, Chua HC. Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese. Am J Med Genet 2000; 96: 712-715.
64. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 1989; 570: 176-185.
65. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 1999; 25: 731-740.
66. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990; 28:535-539.
67. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998; 155: 1207-1213.
68. Cadet JL, Perumal AS. Chronic treatment with prolixin causes oxidative stress in rat brain. Biol Psychiatry 1990; 28: 738-740.
69. Butterfield DA, Castegna A, Drake J, Scapagnini G, Calabrese V. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr Neurosci 2002; 5: 229-239.
70. Benzi G, Moretti A. Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radic Biol Med 1995; 19: 77-101.
71. Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000; 23: 170-177.
72. Zhang Z, Zhang X, Hou G, Sha W, Reynolds GP. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 2002; 36: 317-324.
73. Kimura T, Shono M, Yokota S, Ishizuka K, Watanabe M, Takamatsu I et al. Apolipoprotein E epsilon4 and tardive dyskinesia in a Japanese population. J Psychiatr Res 2000; 34: 329-332.
74. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14: 55-61.
75. Krukoff TL. Central actions of nitric oxide in regulation of autonomic functions. Brain Res Brain Res Rev 1999; 30: 52-65.
76. Yun HY, Dawson VL, Dawson TM. Nitric oxide in health and disease of the nervous system. Mol Psychiatry 1997; 2: 300-310.
77. Shinkai T, Ohmori O, Matsumoto C, Hari H, Kennedy JL, Nakamura J. Genetic association analysis of neuronal nitric oxide synthase (NOS1) gene polymorphism with tardive dyskinesia. (in press).
78. Ohmori O, Shinkai T, Hari H, Kojima H, Nakamura J. Polymorphisms of mu and delta opioid receptor genes and tardive dyskinesia in patients with schizophrenia. Schizophr Res 2001; 52: 137-138.
79. Lai IC, Liao DL, Bai YM, Lin CC, Yu SC, Chen JY et al. Association study of the estrogen receptor polymorphisms with tardive dyskinesia in schizophrenia. Neuropsychobiology 2002; 46: 173-175.
80. Jenkins TA, Mendelsohn FA, Chai SY. Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J Neurochem 1997; 68: 1304-1311.
81. Segman RH, Shapira Y, Modai I, Hamdan A, Zislin J, Heresco-Levy U et al. Angiotensin converting enzyme gene insertion/deletion polymorphism: case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia. Am J Med Genet 2002; 114: 310-314.
82. Karoum F, Chrapusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of anti-psychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 1994; 63: 972-979.
83. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517-2530.
84. Potkin SG, Kennedy JL, Basile VS. Combining brain imaging and pharmacogenetics in understanding clinical response in Alzheimer's disease and schizophrenia. In: Lerer B (ed) Pharmacogenetics of Psychotropic Drugs. Cambridge University Press: Cambridge, UK 2002; pp 391-397, and Fig 319 pp 192b.
85. Ohmori O, Shinkai T, Hori H, Nakamura J. Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia. Psychiatry Res 2002; 110: 97-102.